Bristol Myers Squibb appoints Cristian Massacesi as chief medical officer and head of development

July 28, 2025
Research and Development Bristol Myer Squibb, Corporate, Executive Leadership Team, Head of Development, chief medical officer, executive vice president

Bristol Myers Squibb (BMS) has announced the appointment of Cristian Massacesi as executive vice president, chief medical officer, and head …

Neuraxpharm appoints Avendran Naidu as head of commercial upon launch of Australian affiliate

July 28, 2025
Manufacturing and Production, Research and Development Neuraxpharm, Neuraxpharm Australia, Neurology, central nervous system, multiple sclerosis

Neuraxpharm Group has announced the launch of Neuraxpharm Australia, furthering its global expansion beyond Europe and into key international markets. …

mental-health-3332122_960_720

Seaport Therapeutics doses first patient in trial of GlyphAllo for depression

July 25, 2025
Research and Development Psychiatry, Seaport Therapeutics, clinical trial, major depressive disorder, mental health, neuropsychiatric conditions

Seaport Therapeutics has dosed its first patient in its phase 2b BUOY-1 study of GlyphAllo (SPT-300), an oral prodrug of …

Cube Biotech appoints Michael Bencak as new CEO amid global expansion plans

July 25, 2025
Mergers and Acquisitions, Research and Development CEO, Corporate, Cube Biotech, IBA Lifescience, archimed, executive chairman

Cube Biotech has announced a leadership transition as the company continues its trajectory of global growth and innovation in protein …

PureTech Health appoints interim CEO Robert Lyne

July 24, 2025
Research and Development Corporate, PureTech Health, board of directors, chief portfolio officer, interim CEO

PureTech Health has announced the departure of chief executive officer (CEO) Bharatt Chowrira, who has stepped down from his role …

eyeimagenotext-1

OKYO Pharma reports promising phase 2 results for urcosimod in neuropathic corneal pain

July 24, 2025
Research and Development OKYO Pharma, Opthalmology, clinical trial, neuropathic corneal pain, ocular pain

OKYO Pharma has announced positive results from its phase 2 trial of urcosimod (formerly OK-101) in neuropathic corneal pain (NCP), …

Yourgene Health launches LightBench Discover for long-read sequencing labs

July 23, 2025
Business Services, Technical Consultancy Devices, Novacyt, PacBio, Yourgene Health, molecular diagnostics

Yourgene Health, part of the Novacyt group, has announced the launch of LightBench Discover, an integrated benchtop instrument designed to …

handshake-1910702_960_720

Evestia Clinical and Atlantic Research Group merge to create global specialist CRO

July 23, 2025
Clinical Trial Services, Mergers and Acquisitions, Research and Development Atlantic Research Group, Corporate, Evestia Clinical, clinical trials, contract research organisation

UK-based Evestia Clinical will merge with US-based Atlantic Research Group (ARG), forming a leading independent global contract research organisation (CRO) …

MetP Pharma releases positive data on intranasal semaglutide administration

July 22, 2025
Research and Development Diabetes, MetP Pharma, Neurology, Obesity, central nervous system, diabetes, obesity, peptides, semaglutide

MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering neuroactive peptides, particularly semaglutide, directly …

Takara and Macherey-Nagel enter distribution agreement for global expansion

July 22, 2025
Mergers and Acquisitions Devices, Macherey-Nagel, Microbiology, Takara, Takara Bio Europe

Takara Bio Europe has entered into a distribution agreement with Macherey-Nagel (MN), an analytical and bioanalytical product provider, to expand …

Boehringer Ingelheim and LEO Pharma partner to develop treatment for generalised pustular psoriasis

July 21, 2025
Medical Communications, Mergers and Acquisitions, Research and Development Boehringer Ingelheim, Dermatology, LEO Pharma, Spevigo, generalised pustular psoriasis, partnership, skin disease

Boehringer Ingelheim and LEO Pharma have partnered to commercialise and further develop Spevigo (spesolimab), a treatment for generalised pustular psoriasis …

LDC strengthens healthcare focus with appointment of Amit Thaper as investment director

July 21, 2025
Business Services, Industry Associations, Research and Development Corporate, Inicio Health, Investment Director, LDC, RDi

LDC, the private equity arm of Lloyds Banking Group, has strengthened its healthcare expertise with the appointment of Amit Thaper …

1200px-vaccine_image_1

EMA lifts temporary ban on chikungunya vaccine Ixchiq following safety review

July 18, 2025
Medical Communications Committee for Medicinal Products for Human USE, European Medicines Agency (EMA), Ixchiq, Pharmacovigilance Risk Assessment Committee (PRAC), Vaccine, Virology, chikungunya

After completing a safety review of Ixchiq โ€“ a vaccine for chikungunya โ€“ the European Medicines Agencyโ€™s (EMA) safety committee …

Addenbrookeโ€™s hospital offers first self-service digital eye test

July 17, 2025
Research and Development Addenbrooke's Hospital, Cambridge, Opthalmology, UK, eye test, ophthalmology

Addenbrookeโ€™s Hospital, Cambridge, has become the first in the UK to deploy a digital self-testing system โ€“ DigiVis DVA system …

trial

Biogen and Stoke report positive results for Dravet syndrome drug

July 17, 2025
Research and Development Biogen, Dravet Syndrome, Neurology, Stoke Therapeutics, epilepsy, rare diseases

Biogen and Stoke Therapeutics have shared encouraging new data for their experimental treatment, zorevunersen, which is being developed for Dravet …

Vaccine image

FDA approves Modernaโ€™s Spikevax for children at increased risk of COVID-19

July 16, 2025
Medical Communications COVID-19, Spikevax, US Food and Drug Administration, Vaccine, Virology

Moderna has been granted US Food and Drug Administration (FDA) approval for its COVID-19 vaccine, Spikevax, in children aged six …

Jazz Pharmaceuticals appoints Renรฉe Galรก as CEO to lead next phase of growth

July 16, 2025
Research and Development CEO, Corporate, Neurology, Oncology, jazz pharmaceuticals, neurology, neuroscience

Jazz Pharmaceuticals has named Renรฉe Galรก as its next chief executive officer (CEO), effective 11 August 2025. Galรก, currently president …

Osivax publishes positive results from trial of influenza vaccine candidate

July 15, 2025
Research and Development Osivax, Vaccine, Virology, clinical trial, influenza, respiratory diseases

French biopharma, Osivax, has announced positive results from its phase 2 study, OVX836-004, into OVX836, its broad-spectrum influenza vaccine lead …

The Gateway to Local Adoption Series

Latest content